Randomized phase III clinical trial designs for targeted agents (Q42165255)

17 October 2017

Randomized phase III clinical trial designs for targeted agents (English)

1 reference

17 October 2017

phase III clinical trial

0 references

1

Antje Hoering

1 reference

17 October 2017

Mike Leblanc

2

1 reference

17 October 2017

John J Crowley

series ordinal

3

1 reference

17 October 2017

language of work or name

English

0 references

publication date

1 July 2008

1 reference

17 October 2017

Clinical Cancer Research

1 reference

17 October 2017

14

1 reference

17 October 2017

14

1 reference

17 October 2017

4358-4367

1 reference

Clinical trial designs for multiple myeloma.

17 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569946

Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569946

Erlotinib in previously treated non-small-cell lung cancer

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569946

Clinical trial designs for predictive marker validation in cancer treatment trials

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569946

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569946

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569946

Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569946

Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569946

Issues in clinical trial design for tumor marker studies

17 August 2018

1 reference

12 December 2020

Evaluating the efficiency of targeted designs for randomized clinical trials

1 reference

12 December 2020

Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients

1 reference

12 December 2020

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

1 reference

12 December 2020

10.1158/1078-0432.CCR-08-0288

Identifiers

DOI

1 reference

release_h7tybjwkkjaipbr3ql2bhk6oj4

17 October 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/h7tybjwkkjaipbr3ql2bhk6oj4

24 November 2022

mapped directly with Wikidata item

1 reference

17 October 2017

1 reference